AXGN

SEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,427

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.

SEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 259,297

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.

SEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · derivative · entry 6

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · derivative · entry 5

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · nonDerivative · entry 4

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,734

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.

SEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · nonDerivative · entry 3

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.

SEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · nonDerivative · entry 2

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,702

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.

SEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · nonDerivative · entry 1

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,276

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.

SEC source: 0000805928-26-000044 · wk-form4_1772493414.xml · nonDerivative · entry 3

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,451

F5 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of restricted stock units ("RSUs").

SEC source: 0000805928-26-000043 · wk-form4_1772493371.xml · nonDerivative · entry 3

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,934

F3 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of restricted stock units ("RSUs").

SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · derivative · entry 6

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock.

F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the RSUs will be fully vested on March 1, 2027 based on a vesting schedule whereby 50% of the aggregate shares vest on March 1, 2025, and an additional 25% of the aggregate shares vest each twelve months thereafter. Vested shares will be delivered to the Reporting Person upon the vesting date. The RSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4).

F7 · derivative.expiration_date: All shares of Axogen, Inc. common stock underlying the RSUs will be fully vested on March 1, 2027 based on a vesting schedule whereby 50% of the aggregate shares vest on March 1, 2025, and an additional 25% of the aggregate shares vest each twelve months thereafter. Vested shares will be delivered to the Reporting Person upon the vesting date. The RSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4).

SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · nonDerivative · entry 4

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,135

F4 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of RSUs.

SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · nonDerivative · entry 3

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 1, 2026.

SEC source: 0000805928-26-000038 · wk-form4_1772227303.xml · derivative · entry 3

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000038 · wk-form4_1772227303.xml · nonDerivative · entry 2

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,276

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale.

SEC source: 0000805928-26-000038 · wk-form4_1772227303.xml · nonDerivative · entry 1

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,906

F1 · shares: This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria.

SEC source: 0000805928-26-000036 · wk-form4_1772227199.xml · derivative · entry 1

DALE MICHAEL D · CIK 0001172346 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,000

Underlying: Common Stock · 98,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000044 · wk-form4_1772493414.xml · derivative · entry 4

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires not disclosed

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F7 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F7 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000044 · wk-form4_1772493414.xml · nonDerivative · entry 2

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,403

F4 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of performance stock units ("PSUs").

SEC source: 0000805928-26-000044 · wk-form4_1772493414.xml · nonDerivative · entry 1

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,817

F1 · shares: This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria.

F2 · balance_after: The previous Form 4 filed by the Reporting Person overstated the number of shares beneficially owned by the Reporting Person by 4,003 shares of Common Stock. The amount reported herein has been corrected.

F3 · balance_after: Includes 2,120 shares acquired under the Axogen Employee Stock Purchase Plan on December 31, 2025.

SEC source: 0000805928-26-000043 · wk-form4_1772493371.xml · derivative · entry 4

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000043 · wk-form4_1772493371.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,210

F2 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of performance stock units ("PSUs").

SEC source: 0000805928-26-000043 · wk-form4_1772493371.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 274,912

F1 · shares: This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria.

SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · derivative · entry 5

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires not disclosed

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock.

F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the RSUs will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the RSUs will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · nonDerivative · entry 2

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,312

F2 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of performance stock units ("PSUs").

SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · nonDerivative · entry 1

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,065

F1 · shares: This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria.

SEC source: 0000805928-26-000032 · wk-form4_1771968389.xml · derivative · entry 3

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 22, 2028 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 22, 2026 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 22, 2028 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 22, 2026 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000032 · wk-form4_1771968389.xml · nonDerivative · entry 2

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,453

F2 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Class A Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of restricted stock units ("RSUs").

SEC source: 0000805928-26-000032 · wk-form4_1771968389.xml · nonDerivative · entry 1

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,157

F1 · balance_after: Includes 2,281 shares acquired under the Axogen Employee Stock Purchase Plan on December 31, 2025.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · derivative · entry 9

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Board of Directors' non-qualified stock option grant that vested in full June 6, 2025.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · derivative · entry 8

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,436 shares

Expires 2033-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Board of Directors' non-qualified stock option grant that vested in full September 1, 2024.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · derivative · entry 7

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2026-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Board of Directors' non-qualified stock option grant that vested in full May 26, 2017.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 6

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,826

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 5

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,074

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 4

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,510

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 3

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,826

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000177 · wk-form4_1766006701.xml · derivative · entry 7

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,651

Underlying: Common Stock · 21,825 shares

Expires 2033-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 20, 2024.

SEC source: 0000805928-25-000177 · wk-form4_1766006701.xml · derivative · entry 6

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Non-qualified stock option portion of the annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant fully vested on June 6, 2025, the one-year anniversary of the date of the grant.

SEC source: 0000805928-25-000177 · wk-form4_1766006701.xml · nonDerivative · entry 5

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0000805928-25-000177 · wk-form4_1766006701.xml · nonDerivative · entry 4

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,580

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.01 to $30.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000177 · wk-form4_1766006701.xml · nonDerivative · entry 3

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,405

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.01 to $30.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000177 · wk-form4_1766006701.xml · nonDerivative · entry 2

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,653

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000177 · wk-form4_1766006701.xml · nonDerivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,828

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000176 · wk-form4_1766006686.xml · derivative · entry 3

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,812 shares

Expires 2033-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-25-000176 · wk-form4_1766006686.xml · nonDerivative · entry 2

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,376

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.875 to $29.860 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000176 · wk-form4_1766006686.xml · nonDerivative · entry 1

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000170 · wk-form4_1765573554.xml · nonDerivative · entry 1

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,285

SEC source: 0000805928-25-000171 · wk-form4_1765573574.xml · nonDerivative · entry 1

DALE MICHAEL D · CIK 0001172346 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,537